the Company is exploring development of a new Phase III clinical trial protocol
News | Heart Failure
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs

September 8, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home September 08, 2023
Home
MPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023
News | Cardiovascular Clinical Studies
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

September 8, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing ...

Home September 08, 2023
Home
Patients of African ancestry with dilated cardiomyopathy (DCM) are less likely to have clinically actionable variants in DCM genes than those of European ancestry
News | Cardiovascular Clinical Studies
Study Highlights Need for Diversity in Clinical Trials to Better Understand, Treat Inherited Heart Muscle Disease

September 8, 2023 — Patients of African ancestry with dilated cardiomyopathy (DCM) are less likely to have clinically ...

Home September 08, 2023
Home
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety
News | Left Atrial Appendage (LAA) Occluders
Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX Pro Left Atrial Appendage Closure Device

September 7, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration approval ...

Home September 07, 2023
Home
Recipient of the Harry Goldblatt Award for New Investigators from the American Heart Association’s 2023 Hypertension Council
News | Hypertension
Faulkner to be Honored by American Heart Association

September 7, 2023 —Jessica Faulkner, PhD, a physiologist whose research is focused on sex differences in cardiovascular ...

Home September 07, 2023
Home
Exclusive agreement for AI algorithms to accelerate earlier detection of cardiac amyloidosis and pulmonary hypertension
News | Artificial Intelligence
Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms

September 7, 2023 — Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, announced that ...

Home September 07, 2023
Home
Vektor Medical has announced the release of a series of software enhancements to its AI-based non-invasive solution, vMap, which were designed to improve ablation outcomes and procedural efficiencies.
News | Artificial Intelligence
Vektor Medical Announces Enhanced AI-based vMap for Improved Cardiac Ablation Outcomes, Non-Invasive Mapping of Cardiac Arrhythmias

September 7, 2023 — Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead ...

Home September 07, 2023
Home
Annual Scientific Symposium will take place October 23-26 in San Francisco
Feature | TCT
CRF Announces TCT 2023 Late-breaking Clinical Trials

September 6, 2023 — The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 late-breaking clinical ...

Home September 06, 2023
Home
The diagnosed severity of aortic stenosis strongly correlates with clinical outcomes, new Kaiser Permanente research shows
News | Structural Heart
Large Kaiser Permanente Study Could Lead to Better Management for Patients with Aortic Stenosis

September 6, 2023 — The diagnosed severity of aortic stenosis strongly correlates with clinical outcomes, new Kaiser ...

Home September 06, 2023
Home
Updated AI-based software is designed to improve cardiac ablation outcomes and procedural efficiencies
News | ECG
Vektor Medical Unveils Enhanced vMap Technology for Accurate, Non-invasive Mapping of Cardiac Arrhythmias

September 6, 2023 — Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead ...

Home September 06, 2023
Home
Magenta Medical, developer of the Elevate heart pump system, an FDA Designated Breakthrough Device, recently announced the completion of its FDA-approved Early Feasibility Study for the high-risk percutaneous coronary intervention (HR-PCI) indication.
News | Cardiovascular Clinical Studies
Magenta Medical Completes Enrollment to Early Feasibility Study for World’s Smallest Heart Pump

September 6, 2023 — Magenta Medical, developer of the Elevate heart pump system, an FDA Designated Breakthrough Device ...

Home September 06, 2023
Home
GE HealthCare and Mass General Brigham have announced the co-development of an artificial intelligence (AI) algorithm that will help increase operations effectiveness and productivity.
News | Artificial Intelligence
Mass Gen Brigham and GE HealthCare Collaboration Announces AI Algorithm, Radiology Operations Module (ROM), to Optimize Scheduling and Productivity

September 6, 2023 — GE HealthCare and Mass General Brigham have announced, as part of its initial collaboration, the co ...

Home September 06, 2023
Home
Results from Two Phase 3 studies evaluating CAMZYOS (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy (HCM) were recently released by Bristol Myers Squibb.
News | Cardiovascular Clinical Studies
Results from Two Phase 3 Studies Evaluating Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Released

September 5, 2023 — New long-term follow-up results from two Phase 3 studies evaluating CAMZYOS (mavacamten), a first-in ...

Home September 05, 2023
Home
DAIC GE Vscan Air SL image
News | Cardiac Diagnostics
Wireless Handheld Ultrasound Device Launched by GE HealthCare for Rapid Assessment of Cardiac and Vascular Patients

September 5, 2023 — GE HealthCare announced the launch of a handheld, wireless ultrasound imaging system designed for ...

Home September 05, 2023
Home
The Ohio State University Wexner Medical Center randomized the first patient in the world in a clinical trial evaluating the effectiveness of a device designed to alleviate heart failure symptoms.
News | Cardiovascular Clinical Studies
Ohio State First in World to Participate in Trial of Device Designed to Alleviate Heart Failure Symptoms

September 5, 2023 — The Ohio State University Wexner Medical Center randomized the first patient in the world in a ...

Home September 05, 2023
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now